BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 19601812)

  • 1. Developmental abnormalities and cancer predisposition in neurofibromatosis type 1.
    Larizza L; Gervasini C; Natacci F; Riva P
    Curr Mol Med; 2009 Jun; 9(5):634-53. PubMed ID: 19601812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neurofibromin - protein structure and cellular functions in the context of neurofibromatosis type I pathogenesis].
    Abramowicz A; Gos M
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1331-48. PubMed ID: 26671924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway.
    Ozawa T; Araki N; Yunoue S; Tokuo H; Feng L; Patrakitkomjorn S; Hara T; Ichikawa Y; Matsumoto K; Fujii K; Saya H
    J Biol Chem; 2005 Nov; 280(47):39524-33. PubMed ID: 16169856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatiotemporal Loss of
    Chen Z; Mo J; Brosseau JP; Shipman T; Wang Y; Liao CP; Cooper JM; Allaway RJ; Gosline SJC; Guinney J; Carroll TJ; Le LQ
    Cancer Discov; 2019 Jan; 9(1):114-129. PubMed ID: 30348677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in neurofibromatosis type 1.
    Lee MJ; Stephenson DA
    Curr Opin Neurol; 2007 Apr; 20(2):135-41. PubMed ID: 17351482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner.
    Brown JA; Diggs-Andrews KA; Gianino SM; Gutmann DH
    Mol Cell Neurosci; 2012 Jan; 49(1):13-22. PubMed ID: 21903164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular, genetic, and cellular pathogenesis of neurofibromas and surgical implications.
    Gottfried ON; Viskochil DH; Fults DW; Couldwell WT
    Neurosurgery; 2006 Jan; 58(1):1-16; discussion 1-16. PubMed ID: 16385324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer.
    Rad E; Tee AR
    Semin Cell Dev Biol; 2016 Apr; 52():39-46. PubMed ID: 26860753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
    Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
    Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofibromin-deficient Schwann cells have increased lysophosphatidic acid dependent survival and migration-implications for increased neurofibroma formation during pregnancy.
    Nebesio TD; Ming W; Chen S; Clegg T; Yuan J; Yang Y; Estwick SA; Li Y; Li X; Hingtgen CM; Yang FC
    Glia; 2007 Apr; 55(5):527-36. PubMed ID: 17236191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
    Ratner N; Miller SJ
    Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
    Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
    Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes.
    Dasgupta B; Dugan LL; Gutmann DH
    J Neurosci; 2003 Oct; 23(26):8949-54. PubMed ID: 14523097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NF1 gene in tumor syndromes and melanoma.
    Kiuru M; Busam KJ
    Lab Invest; 2017 Feb; 97(2):146-157. PubMed ID: 28067895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.
    Stansfield BK; Bessler WK; Mali R; Mund JA; Downing BD; Kapur R; Ingram DA
    Am J Pathol; 2014 Jan; 184(1):79-85. PubMed ID: 24211110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis.
    Patritti Cram J; Wu J; Coover RA; Rizvi TA; Chaney KE; Ravindran R; Cancelas JA; Spinner RJ; Ratner N
    Elife; 2022 Mar; 11():. PubMed ID: 35311647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning.
    Anastasaki C; Woo AS; Messiaen LM; Gutmann DH
    Hum Mol Genet; 2015 Jun; 24(12):3518-28. PubMed ID: 25788518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical interaction between neurofibromin and serotonin 5-HT6 receptor promotes receptor constitutive activity.
    Deraredj Nadim W; Chaumont-Dubel S; Madouri F; Cobret L; De Tauzia ML; Zajdel P; Bénédetti H; Marin P; Morisset-Lopez S
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12310-12315. PubMed ID: 27791021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.